ArticleSchizophrenia (Heidelberg, Germany)2022
Validation of accelerometry as a digital phenotyping measure of negative symptoms in schizophrenia.
Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Digital Phenotyping for Monitoring Mental Disorders: Systematic Review.Journal of medical Internet research · 2023Pooled it
- Mobile Technology for Real-Life Assessment of Positive and Negative Symptoms as well as Stress Among Individuals With Early Psychosis: A Scoping Review.Early intervention in psychiatry · 2026Article
- AI-enabled digital phenotyping for Alzheimer's disease: a review of multimodal sensor integration and symptom trajectories.Alzheimer's research & therapy · 2026Review
- Smartphone-Based Digital Phenotyping Across Health Conditions: Scoping Review.Journal of medical Internet research · 2026Article
- Subjective Perceptions of Digital Phenotyping Measures of Negative Symptoms Among Individuals At Clinical High Risk for Psychosis and Their Relatives.Schizophrenia bulletin open · 2026Article
- Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.Neuroscience applied · 2026Review
- Environmental deprivation is associated with reward processing impairments and negative symptoms in schizophrenia.Schizophrenia research · 2025Article
- Digital phenotyping evidence for the reduced positivity offset as a mechanism underlying anhedonia among individuals at clinical high-risk for psychosis.Schizophrenia research · 2025Article
- Passive Smartphone Sensors for Detecting Psychopathology.JAMA network open · 2025Article
- Utility of Digital Phenotyping Based on Wrist Wearables and Smartphones in Psychosis: Observational Study.JMIR mHealth and uHealth · 2025Observational
- Forecasting mental states in schizophrenia using digital phenotyping data.PLOS digital health · 2025Article
- A systematic review of passive data for remote monitoring in psychosis and schizophrenia.NPJ digital medicine · 2025Article
- Behavioural digital biomarkers enable real-time monitoring of patient-reported outcomes: a substudy of the multicentre, prospective observational SafeHeart study.European heart journal. Quality of care & clinical outcomes · 2024Observational
- Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms.Schizophrenia bulletin open · 2024Review
- Digital Phenotyping in Adults with Schizophrenia: A Narrative Review.Current psychiatry reports · 2023Review
- Environmental resource reductions predict greater severity of negative symptoms in schizophrenia.Schizophrenia research · 2023Article
- Digital Phenotyping: Data-Driven Psychiatry to Redefine Mental Health.Journal of medical Internet research · 2023Article
- Digital health literacy and digital engagement for people with severe mental ill health across the course of the COVID-19 pandemic in England.BMC medical informatics and decision making · 2023Article
- Using Smartphones to Identify Momentary Characteristics of Persecutory Ideation Associated With Functional Disability.Schizophrenia bulletin open · 2023Article
- Impaired Effort Allocation in Patients with Recent-Onset Schizophrenia and Its Relevance to Negative Symptoms Assessments and Persistent Negative Symptoms.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Negative symptoms are commonly assessed via clinical rating scales; however, these measures have several inherent limitations that impact validity and utility for their use in clinical trials. Objective digital phenotyping measures that overcome some of these limitations are now available. The current study evaluated the validity of accelerometry (ACL), a passive digital phenotyping method that involves collecting data on the presence, vigor, and variability of movement. Outpatients with schizophrenia (SZ: n = 50) and demographically matched healthy controls (CN: n = 70) had ACL continuously recorded from a smartphone and smartband for 6 days. Active digital phenotyping assessments, including surveys related to activity context, were also collected via 8 daily surveys throughout the 6 day period. SZ participants had lower scores on phone ACL variables reflecting vigor and variability of movement compared to CN. ACL variables demonstrated convergent validity as indicated by significant correlations with active digital phenotyping self-reports of time spent in goal-directed activities and clinical ratings of negative symptoms. The discriminant validity of ACL was demonstrated by low correlations with clinical rating scale measures of positive, disorganized, and total symptoms. Collectively, findings suggest that ACL is a valid objective measure of negative symptoms that may complement traditional approaches to assessing the construct using clinical rating scales.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.